GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

prasinezumab   Click here for help

GtoPdb Ligand ID: 13330

Synonyms: PRX002 | RG-7935 | RG7935 | RO-7046015 | RO7046015
Compound class: Antibody
Comment: Prasinezumab (RO7046015) is a monoclonal antibody that binds the C-terminus of neurotoxic (aggregated) forms of α-synuclein. It was designed to reduce the cell-to-cell spread of toxic α-synuclein aggregates in the brains of people with Parkinson's disease, as a disease-modifying therapeutic approach to slow the rate of neuronal damage and disease progression.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Prasinezumab was progressed as a clinical candidate, to determine safety and efficacy in patients with early Parkinson's disease [3,8-9].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04777331 A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease Phase 2 Interventional Hoffmann-La Roche The PADOVA trial 6
NCT07174310 A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease Phase 3 Interventional Hoffmann-La Roche The PARISO trial
NCT03100149 A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease Phase 2 Interventional Hoffmann-La Roche The PASADENA trial 7-8